Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 5, 2010, Pages 656-664

  Keire, David A ^a   Mans, Daniel J ^a   Ye, Hongping ^a   Kolinski, Richard E ^a   Buhse, Lucinda F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Carbohydrates; Glycosaminoglycans; Heparin; NMR; Oversulfated; SAX HPLC

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHONDROITIN 4 SULFATE; DERMATAN SULFATE; DRUG ADDITIVE; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARAN SULFATE; HEPARIN; PROTHROMBIN A;

ANALYTIC METHOD; ANION EXCHANGE CHROMATOGRAPHY; ANTICOAGULATION; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG IMPURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SIGNAL DETECTION; STANDARDIZATION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEPARIN; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS; PROTONS;

EID: 77950867423     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.02.019     Document Type: Article

References (26)

1. Liu H., Zhang Z., Linhardt R.J. Lessons learned from the contamination of heparin. Nat. Prod. Rep. 2009, 26:313-321.
2. Rabenstein D.L. Heparin and heparan sulfate: structure and function. Nat. Prod. Rep. 2002, 19:312-331.
3. Fischer K.G. Essentials of anticoagulation in hemodialysis. Hemodial. Int. 2007, 11:178-189.
4. Lepor N.E. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev. Cardiovasc. Med. 2007, 8(Suppl. 3):S9-S17.
5. Guerrini M., Zhang Z., Shriver Z., Naggi A., Masuko S., Langer R., Casu B., Linhardt R.J., Torri G., Sasisekharan R. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc. Natl. Acad. Sci. 2009.
6. WHO Contaminant Detected in Heparin Material of Specified Origin in the USA and in Germany; Serious Adverse Events Reported; Recall Measures Initiated. World Health Organization Alert, No. 118 2008, (7 March 2008). http://www.int/medicines/publications/drugalerts/Alert_118_Heparin.pdf.
7. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Gunay N.S., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
8. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
9. Griffin C.C., Linhardt R.J., Van Gorp C.L., Toida T., Hileman R.E., Schubert R.L., Brown S.E. Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. Carbohydr. Res. 1995, 276:183-197.
10. Imanari T., Toida T., Koshiishi I., Toyoda H. High-performance liquid chromatographic analysis of glycosaminoglycan-derived oligosaccharides. J. Chromatogr. A 1996, 720:275-293.
11. Patel R.P., Narkowicz C., Hutchinson J.P., Hilder E.F., Jacobson G.A. A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J. Pharm. Biomed. Anal. 2008, 46:30-35.
12. Turnbull J.E. Analytical and preparative strong anion-exchange HPLC of heparan sulfate and heparin saccharides. Methods Mol. Biol. 2001, 171:141-147.
13. Volpi N., Maccari F., Linhardt R.J. Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations. Anal. Biochem. 2009, 388:140-145.
14. Wielgos T., Havel K., Ivanova N., Weinberger R. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers. J. Pharm. Biomed. Anal. 2009, 49:319-326.
15. Korir A.K., Larive C.K. Advances in the separation, sensitive detection, and characterization of heparin and heparan sulfate. Anal. Bioanal. Chem. 2009, 393:155-169.
16. Limtiaco J.F., Jones C.J., Larive C.K. Characterization of heparin impurities with HPLC-NMR using weak anion exchange chromatography. Anal. Chem. 2009, 81:10116-10123.
17. Trehy M.L., Reepmeyer J.C., Kolinski R.E., Westenberger B.J., Buhse L.F. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J. Pharm. Biomed. Anal. 2009, 49:670-673.
18. Beyer T., Diehl B., Randel G., Humpfer E., Schafer H., Spraul M., Schollmayer C., Holzgrabe U. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 2008, 48:13-19.
19. McEwen I., Mulloy B., Hellwig E., Kozerski L., Beyer T., Holzgrabe U., Wanko R., Spieser J.M., Rodomonte A. Determination of oversulphated chondroitin sulphate and dermatan sulphate in unfractionated heparin by (1)H-NMR-collaborative study for quantification and analytical determination of LoD. Pharmeuropa Bio 2008, 2008:31-39.
20. D.A. Keire, M.L. Trehy, J.C. Reepmeyer, R.E. Kolinski, W. Ye, J. Dunn, B.J. Westenberger, L.F. Buhse, Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate, J. Pharm. Biomed. Anal. (E-Pub December 2009).
21. Zhang Z., Li B., Suwan J., Zhang F., Wang Z., Liu H., Mulloy B., Linhardt R.J. Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE. J. Pharm. Sci. 2009.
22. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 1998, 306:35-43.
23. Toida T., Maruyama T., Ogita Y., Suzuki A., Toyoda H., Imanari T., Linhardt R.J. Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans. Int. J. Biol. Macromol. 1999, 26:233-241.
24. Chen J., Avci F.Y., Munoz E.M., McDowell L.M., Chen M., Pedersen L.C., Zhang L., Linhardt R.J., Liu J. Enzymatic redesigning of biologically active heparan sulfate. J. Biol. Chem. 2005, 280:42817-42825.
25. Guerrini M., Naggi A., Guglieri S., Santarsiero R., Torri G. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal. Biochem. 2005, 337:35-47.
26. Toida T., Sakai S., Akiyama H., Linhardt R.J. Chondroitin sulfate structure, role and pharmacological activity. Advances in Pharmacology 2006, 403-415. Elsevier. N. Volpi (Ed.).